StockDrifts LogoStockDrifts

bioprotech 199290

Company
바이오프로테크bioprotech
Insiders
0
Buys
0
Total Value
Avg Return
Last Filing
2026-05-31

bioprotech (199290) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for bioprotech is dated 2023-12-11; the most recent is 2026-05-31. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-05-31SELL임원퇴임
이병탁
Lee Byung-tak
committee member-25.0K₩410-6.1%₩10M ($7K)
2024-10-07SELL증여
이성제
Lee Seong-je
Managing Director-100.1K₩500+28.0%₩50M ($35K)
2024-03-15BUY기타
김병전
Kim Byeong-jeon
CEO16.3K₩1,099-67.2%₩18M ($12K)
2024-03-15BUY기타
임재상
Jaesang Lim
moving39.1K₩1,099-67.2%₩43M ($30K)
2024-03-15BUY기타
석희복
Seok Hee-bok
Managing Director19.5K₩1,099-67.2%₩21M ($15K)
2024-03-15BUY기타
박익로
Park Ik-ro
CEO1.9K₩1,099-67.2%₩2M ($1K)
2024-03-15BUY기타
이성제
Lee Seong-je
Managing Director39.1K₩1,099-67.2%₩43M ($30K)
2024-03-15SELL기타
케이씨-쥐피(KC-GP) 신기술조합 제일호
KC-GP New Technology Association Jeilho
--5.1M₩1,099+67.2%₩5.6B ($3.9M)
2023-12-11BUY수증
석희복
Seok Hee-bok
Managing Director1.1K₩1,238-70.9%₩1M ($924)

Frequently asked questions

Who has been buying bioprotech stock?
0 distinct insiders have filed 0 disclosed insider purchases in bioprotech (199290), most recently on 2026-05-31. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does bioprotech have?
bioprotech has 0 buy-side and 0 sell-side disclosures on record, spanning 2023-12-11 to 2026-05-31.
Where does StockDrifts get bioprotech insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for bioprotech. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.